Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
As Meiragtx wows investors with its gene therapy for a cause of blindness, continuing lack of clarity around Gensight’s GS010 prompts more questions than answers.
Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Fibrogen tumbles on a confusing safety update for its most advanced project.
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.